Summary
The role of sentinel node biopsy has increased over the last three years. Nodal status is no longer a main criterion for assignment of systemic adjuvant therapy. In premenopausal patients with clearly hormone dependent disease, endocrine therapy is standard irrespective of chemotherapy. An increased role, especially for goserelin and anthracyclines in the adjuvant therapy of breast cancer has been established. However, more large scale clinical trials are needed.
Several important questions have to be answered in the near future:
-
•
The role of ovarian function suppression associated with tamoxifen
-
•
The role of aromatase inhibitors
-
•
The usefulness of taxanes and the role of high dose chemotherapy in ER/PgR absent disease should be studied
-
•
The role of trastuzumab with chemotherapy should be clarified
The 9th International Conference on Adjuvant Therapy of Primary Breast Cancer (ABC) and Consensus Meeting is planned for March 13th-15th, 2003.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ER:
-
Estrogen receptor
- PgR:
-
Progesterone receptor
References
Meeting Highlights: International consensus panel on the treatment of primary breast cancer.J Clin Oncol 19: 3817–3827, 2001.
Adjuvant Therapy of Primary Breast Cancer 2001. Abstract published in: The Breast 2001, 10 (Suppl 1), ISSN 0960-9776.
Adjuvant Therapy of Primary Breast Cancer 2001. Proceedings, The Breast 2001, 10 (2001).
Author information
Authors and Affiliations
Additional information
Reprint requests to Beat Thuerlimann, Department of Internal Medicine, Kantonsspital, 9007 St. Gallen, Switzerland.
About this article
Cite this article
Thuerlimann, B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast Cancer 8, 294–297 (2001). https://doi.org/10.1007/BF02967527
Issue Date:
DOI: https://doi.org/10.1007/BF02967527